Chardan Capital Initiates Ocular Therapeutix (OCUL) With a Buy Rating

Company Overview - Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on developing sustained-release drug treatments for eye diseases using its ELUTYX hydrogel technology [3]. Analyst Insights - Daniil Gataulin from Chardan Capital initiated coverage on Ocular Therapeutix with a Buy rating and a price target of $21, indicating strong confidence in the company's future performance [1]. - The analyst emphasized the Axpaxli program, which is the company's lead initiative aimed at reducing the treatment burden for patients requiring frequent anti-VEGF injections, commonly used for conditions like wet age-related macular degeneration and non-proliferative diabetic retinopathy [2]. - Gataulin believes that Axpaxli has significant potential to enhance patient outcomes by decreasing the frequency of required treatments, positioning it as a valuable option in the eye care market [2]. - The gradual launch strategy for Axpaxli allows Ocular Therapeutix to effectively manage supply and uptake, which could further support its market position [2].